January 8, 2018 / 1:14 PM / 11 days ago

BRIEF-Newlink Genetics Outlines 2018 Business Priorities

Jan 8 (Reuters) - Newlink Genetics Corp:

* NEWLINK GENETICS OUTLINES 2018 BUSINESS PRIORITIES TO SUPPORT PHASE 3 PIVOTAL TRIAL OF INDOXIMOD PLUS PD-1 INHIBITORS

* NEWLINK GENETICS CORP - ENDED 2017 WITH APPROXIMATELY $158 MILLION IN CASH AND CASH EQUIVALENTS

* NEWLINK GENETICS - ENTERING 2018, HAVE ALIGNED BUSINESS AND INVESTMENTS TO DRIVE INDIGO301 AND OTHER HIGH-POTENTIAL DEVELOPMENT PROGRAMS

* NEWLINK GENETICS CORP - ENROLL MAJORITY OF INDIGO301 TRIAL BY END OF 2018

* NEWLINK GENETICS CORP - PHASE 2 RESULTS FOR INDOXIMOD + PD-1 BLOCKADE IN ADVANCED MELANOMA EXPECTED IN 2018

* NEWLINK GENETICS CORP - PHASE 2 RESULTS FOR INDOXIMOD + GEM/NAB-PACLITAXEL IN PANCREATIC CANCER EXPECTED 1H 2018

* NEWLINK GENETICS CORP - PHASE 2 RANDOMIZED ASTRAZENECA COLLABORATION IN PANCREATIC CANCER TO INITIATE 1H 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below